Connect your AI

Kymera Therapeutics KYMR Total Equity

Total Equity at other companies

PfizerPFE

$90.1B-0.3%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

ImmunityBio, Inc.IBRX

-$870.01M-47.1%

Krystal Biotech, Inc.KRYS

$1.28B+29.7%

Johnson & JohnsonJNJ

——

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's total equity?: Kymera Therapeutics (KYMR) reported total equity of $1.54B in Q1 2026.
How has Kymera Therapeutics's total equity changed year-over-year?: Kymera Therapeutics's total equity increased by 95.8% year-over-year, from $786.23M to $1.54B.
What is the long-term trend for Kymera Therapeutics's total equity?: Over 5 years (2020 to 2025), Kymera Therapeutics's total equity has grown at a 41.0% compound annual growth rate (CAGR), from $283.89M to $1.58B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.